Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis

被引：7

作者：

Greenberg, Benjamin M. ^{[1
]}

Balcer, Laura ^{[3
]}

Calabresi, Peter A. ^{[4
]}

Cree, Bruce ^{[5
]}

Cross, Anne ^{[7
]}

Frohman, Teresa ^{[1
]}

Gold, Ralf ^{[8
]}

Havrdova, Eva ^{[12
]}

Hemmer, Bernhard ^{[9
]}

Kieseier, Bernd C. ^{[10
]}

Lisak, Robert ^{[13
]}

Miller, Aaron ^{[14
]}

Racke, Michael K. ^{[15
]}

Steinman, Lawrence ^{[6
]}

Stuve, Olaf ^{[1
]}

Wiendl, Heinz ^{[11
]}

Frohman, Elliot ^{[1
,2
]}

机构：

[1] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75235 USA

[2] Univ Texas SW Med Ctr Dallas, Dept Ophthalmol, Dallas, TX 75235 USA

[3] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA

[4] Johns Hopkins Univ Hosp, Dept Neurol, Baltimore, MD 21287 USA

[5] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA

[6] Stanford Univ, Dept Neurol, Stanford, CA 94305 USA

[7] Washington Univ, Dept Neurol, St Louis, MO USA

[8] Ruhr Univ Bochum, Dept Neurol, Bochum, Germany

[9] Univ Munich, Dept Neurol, D-80539 Munich, Germany

[10] Univ Dusseldorf, Dept Neurol, Dusseldorf, Germany

[11] Univ Munster, Dept Neurol, D-48149 Munster, Germany

[12] Charles Univ Prague, Dept Neurol, Prague, Czech Republic

[13] Wayne State Univ, Dept Neurol, Detroit, MI USA

[14] Mt Sinai Sch Med, Dept Neurol, New York, NY USA

[15] Ohio State Univ, Dept Neurol, Columbus, OH 43210 USA

来源：

JAMA NEUROLOGY | 2013年 / 70卷 / 02期

基金：

美国国家卫生研究院;

关键词：

PLACEBO-CONTROLLED TRIAL; PROGRESSION;

D O I：

10.1001/jamaneurol.2013.1017

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

[No abstract available]

引用

页码：248 / 251

页数：4

共 50 条

[31] Clinical significance of antibodies to interferon beta therapy in patients with relapsing-remitting multiple sclerosis
Bendtzen, Klaus
[J]. CYTOKINE, 2009, 48 (1-2) : 21 - 21
[32] A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis
Goodin, Douglas S.
[J]. NEUROLOGY, 2006, 67 (07) : 1313 - 1313
[33] Rationale for early treatment with interferon beta-1a in relapsing-remitting multiple sclerosis
Munschauer, FE
Stuart, WH
[J]. CLINICAL THERAPEUTICS, 1997, 19 (05) : 868 - 882
[34] Disability Progression in a Clinical Trial of Relapsing-Remitting Multiple Sclerosis
Rudick, Richard A.
Lee, Jar-Chi
Cutter, Gary R.
Miller, Deborah M.
Bourdette, Dennis
Weinstock-Guttman, Bianca
Hyde, Robert
Zhang, Hao
You, Xiaojun
[J]. ARCHIVES OF NEUROLOGY, 2010, 67 (11) : 1329 - 1335
[35] The effect of interferon beta (IFNB) on location of relapsing-remitting multiple sclerosis (RRMS) relapse
Deen, Serina
High, Andrew
Waubaunt, Emmanuelle
[J]. ANNALS OF NEUROLOGY, 2007, 62 : S14 - S14
[36] Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
Vazquez Gomez, Lazaro Aurelio
Hidalgo Mesa, Carlos
Broche Perez, Yunier
Valdes Morales, Yanet
[J]. MEDISUR-REVISTA DE CIENCIAS MEDICAS DE CIENFUEGOS, 2022, 20 (05): : 825 - 833
[37] Outcome of beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis
K. O'Rourke
C. Walsh
M. Hutchinson
[J]. Journal of Neurology, 2007, 254 : 1547 - 1554
[38] Effectiveness of interferon beta treatment in relapsing-remitting multiple sclerosis: an Italian cohort study
Russo, P
Paolillo, A
Caprino, L
Bastianello, S
Bramanti, P
[J]. JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2004, 10 (04) : 511 - 518
[39] Side effects of interferon-beta 1a in relapsing-remitting multiple sclerosis
Lotfi, J
Adibnejad, S
Beheshtian, A
[J]. JOURNAL OF NEUROLOGY, 2004, 251 : 64 - 64
[40] A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis
Koch-Henriksen, N
Sorensen, PS
Christensen, T
Frederiksen, J
Ravnborg, M
Jensen, K
Heltberg, A
Kristensen, O
Stenager, E
Petersen, T
Hansen, T
[J]. NEUROLOGY, 2006, 66 (07) : 1056 - 1060

← 1 2 3 4 5 →